Virtue® SAB
Coronary In-Stent Restenosis (ISR)
Key Facts
About Orchestra BioMed
Orchestra BioMed is a clinical-stage medical device innovator focused on developing and commercializing high-impact therapeutic solutions for hypertension and atherosclerotic artery disease. The company's strategy centers on a capital-efficient, partnership-enabled model to de-risk development and leverage the commercial infrastructure of established partners. Its late-stage pipeline features two flagship platforms: AVIM Therapy, a bioelectronic treatment for hypertension delivered via pacemakers, and Virtue® SAB, a drug/device combination for treating artery disease without a permanent implant.
View full company profileAbout Orchestra BioMed
Orchestra BioMed is a clinical-stage medical device innovator focused on developing and commercializing high-impact therapeutic solutions for hypertension and atherosclerotic artery disease. The company's strategy centers on a capital-efficient, partnership-enabled model to de-risk development and leverage the commercial infrastructure of established partners. Its late-stage pipeline features two flagship platforms: AVIM Therapy, a bioelectronic treatment for hypertension delivered via pacemakers, and Virtue® SAB, a drug/device combination for treating artery disease without a permanent implant.
View full company profileAbout Orchestra BioMed
Orchestra BioMed is a clinical-stage medical device innovator focused on developing and commercializing high-impact therapeutic solutions for hypertension and atherosclerotic artery disease. The company's strategy centers on a capital-efficient, partnership-enabled model to de-risk development and leverage the commercial infrastructure of established partners. Its late-stage pipeline features two flagship platforms: AVIM Therapy, a bioelectronic treatment for hypertension delivered via pacemakers, and Virtue® SAB, a drug/device combination for treating artery disease without a permanent implant.
View full company profileAbout Orchestra BioMed
Orchestra BioMed is a clinical-stage medical device innovator focused on developing and commercializing high-impact therapeutic solutions for hypertension and atherosclerotic artery disease. The company's strategy centers on a capital-efficient, partnership-enabled model to de-risk development and leverage the commercial infrastructure of established partners. Its late-stage pipeline features two flagship platforms: AVIM Therapy, a bioelectronic treatment for hypertension delivered via pacemakers, and Virtue® SAB, a drug/device combination for treating artery disease without a permanent implant.
View full company profileTherapeutic Areas
Other Coronary In-Stent Restenosis (ISR) Drugs
| Drug | Company | Phase |
|---|---|---|
| Sirolimus-Coated Balloon (SCB) - MAGICAL ISR | Concept Medical | Phase 3 (IDE) |